Re-evaluating the Inhibition of Stress Erosions (REVISE): A protocol for pilot randomized controlled trial

Annals of Saudi Medicine

Volumn 36, Issue 6, 2016, Pages 427-433

  Alhazzani, Waleed ^a   Guyatt, Gordon ^a   Marshall, John C ^b   Hall, Richard ^c   Muscedere, John ^d   Lauzier, Francois ^e   Thabane, Lehana ^a,f   Alshahrani, Mohammed ^g   English, Shane W ^h,i   Arabi, Yaseen M ^j   Deane, Adam M ^k   Karachi, Tim ^a   Rochwerg, Bram ^a   Finfer, Simon ^l   Daneman, Nick ^m   Zytaruk, Nicole ^a   Heel Ansdell, Diane ^a   Cook, Deborah ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^j KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^k UNIVERSITY OF ADELAIDE   (Australia)

^l UNIVERSITY OF SYDNEY   (Australia)

^m UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PANTOPRAZOLE; PLACEBO; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT;

ARTICLE; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MULTICENTER STUDY; PARALLEL DESIGN; PILOT STUDY; PRIORITY JOURNAL; PROGRAM FEASIBILITY; PROPHYLAXIS; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STRESS ULCER; UPPER GASTROINTESTINAL BLEEDING; VENTILATED PATIENT; VENTILATOR ASSOCIATED PNEUMONIA; ADULT; ADVERSE EFFECTS; ARTIFICIAL VENTILATION; CLINICAL PROTOCOL; CLINICAL TRIAL; FEASIBILITY STUDY; FEMALE; MALE; MENTAL STRESS; MIDDLE AGED; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PREVENTION AND CONTROL; TREATMENT WITHDRAWAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; CLINICAL PROTOCOLS; FEASIBILITY STUDIES; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PILOT PROJECTS; RESPIRATION, ARTIFICIAL; STRESS, PSYCHOLOGICAL; WITHHOLDING TREATMENT;

EID: 85013684404     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.5144/0256-4947.2016.427     Document Type: Article

References (33)

1. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. American journal of health-system phar-macy: AJHP: official journal of the American Society of Health-System Pharmacists 1999;56(4):347-79.
2. Dellinger R P, Levy MM, Rhodes A, An-nane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guide-lines for management of severe sepsis and septic shock: 2012. Critical Care Medicine 2013;41(2):580-637.
3. Cook DJ, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, et al. The attributable mortality and length of intensive care unit stay of clinically important gastroin-testinal bleeding in critically ill patients. Crit Care 2001;5(6):368-75.
4. Alhazzani W, Alshahrani M, Moayyedi P, Jaeschke R. Stress ulcer prophylaxis in critically ill patients: review of the evidence. Polskie Archiwum Medycyny Wewnetrznej 2012;122(3):107-14.
5. Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Critical Care Medicine 2010;38(11):2222-8.
6. Lam N P, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Critical Care Medicine 1999;27(1):98-103.
7. Erstad BL, Barletta J F, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Crit Care 1999;3(6):145-49.
8. Barletta J F, Erstad BL, Fortune JB. Stress ulcer prophylaxis in trauma patients. Crit Care 2002;6(6):526-30.
9. Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Critical Care Medicine 2004;32(10):2008-13.
10. Barletta J F, Kanji S, MacLaren R, Lat I, Erstad BL. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. Journal of Critical Care 2014;29(6):955-60.
11. Eastwood GM, Litton E, Bellomo R, Bailey MJ, Festa M, Beasley RW, et al. Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units. Critical Care and Resuscitation 2014;16(3):170-4.
12. Krag M, Perner A, Wetterslev J, Wise M P, Borthwick M, Bendel S, et al. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiologica Scandinavica 2015;59(5):576-85.
13. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Critical Care Medicine 2013;41(3):693-705.
14. Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mu-cosal bleeding prophylaxis in critically ill patients: a meta-analysis. The American Journal of Gastroenterology 2012;107(4):507-20; quiz 21.
15. Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nature Reviews. Gastroenterol-ogy & Hepatology 2012;9(3):132-9.
16. Krag M, Perner A, Wetterslev J, Wise M P, Hylander Moller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Medicine 2014;40(1):11-22.
17. MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs protonpump inhibitors on gastrointestinal tracthemorrhage and infectious complications in the intensive care unit. JAMA Internal Medicine 2014;174(4):564-74.
18. Smith OM, McDonald E, Zytaruk N, Foster D, Matte A, Clarke F, et al. Enhancing the informed consent process for critical care research: strategies from a thromboprophy-laxis trial. Intensive & Critical Care Nursing 2013;29(6):300-9.
19. Walker S, Iazzetta J, Law S. Extended stability of pantoprazole for injection in 0.9% sodium chloride or 5% dextrose at 4 degrees c and 23 degrees c. The Ca-nadian Journal of Hospital Pharmacy 2009;62(2):135-41.
20. Donnelly RF. Stability of pantoprazole sodium in glass vials, polyvinyl chloride minibags, and polypropylene syringes. The Canadian Journal of Hospital Pharmacy 2011;64(3):192-8.
21. Dhaliwal R, Cahill N, Lemieux M, Hey-land DK. The Canadian critical care nutrition guidelines in 2013: an update on current recommendations and implementation strategies. Nutrition in Clinical Practice 2014;29(1):29-43.
22. Smith OM, McDonald E, Zytaruk N, Foster D, Matte A, Clarke F, et al. Rates and determinants of informed consent: a case study of an international thrombo-prophylaxis trial. Journal of Critical Care 2013;28(1):28-39.
23. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. The American Journal of Managed Care 2010;16(9):e228-34.
24. Jacobson BC, Ferris TG, Shea TL, Mah-lis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? The American Journal of Gastroenterology 2003;98(1):51-8.
25. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, et al. Dalte-parin versus unfractionated heparin in critically ill patients. The New England Journal of Medicine 2011;364(14):1305-14.
26. Ego A, Preiser JC, Vincent JL. Impact of diagnostic criteria on the incidence of ventilator-associated pneumonia. Chest 2015;147(2):347-55.
27. Tejerina E, Esteban A, Fernandez-Sego-viano P, Frutos-Vivar F, Aramburu J, Balleste-ros D, et al. Accuracy of clinical definitions of ventilator-associated pneumonia: comparison with autopsy findings. Journal of Critical Care 2010;25(1):62-8.
28. Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary. Chest 2000;117(4 Suppl 2):177S-81S.
29. Singh N, Rogers P, Atwood CW, Wa-gener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. American Journal of Respiratory and Critical Care Medicine 2000;162(2 Pt 1):505-11.
30. Cohen SH, Gerding DN, Johnson S, Kel-ly C P, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control and Hospital Epidemiology 2010;31(5):431-55.
31. Arnold DM, Lauzier F, Rabbat C, Zytaruk N, Barlow Cash B, Clarke F, et al. Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thrombosis Research 2013;131(3):204-9.
32. Cook D, Walter S, Freitag A, Guyatt G, Devitt H, Meade M, et al. Adjudicating ventilator-associated pneumonia in a randomized trial of critically ill patients. Journal of Critical Care 1998;13(4):159-63.
33. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310(20):2191-4.